On the stock market since 2017, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
No real growth (-2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
Sales run at $69.2M a year. A small number, but proof the product has real buyers.
It pays out $0.57 per share each year — regular cash for whoever holds the stock.
A loss of $49.5M against $69.2M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, AHIVX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AHIVX is a high-risk stock — not yet profitable, and its future rides on its product catching on.